



Lyon, July 11th 2013 - The **MEDICREA** Group (FR0004178572-ALMED), which specializes in the development of innovative surgical technologies for the treatment of spinal pathologies, is listed on Alternext by NYSE - Euronext Paris, announces its sales for the 1st half of 2013, ended June 30, 2013.

H1 2013 SALES

	H1 2012	H2 2012	H1 2013	Variation	Variation
				H1 2013 / H1 2012	H1 2013 / H2 2012
Sales (€m)	10.8	9.9	11.9	+10,2%	+20,2%

Variation in foreign currency had no effect on H1 2013 sales

KEY EVENTS

- Record billing over the 2nd quarter: 6.5 million euros
- Record billing in the month of June: 2.9 million euros
- MEDICREA USA exceeded 2 million dollars of billing for the first time in June 2013

ACTIVITY

1st half sales were up +10.2% at 11.9 million euros compared with the same period of 2012, in a market showing no signs of a significant upturn under pressure from pricing cuts imposed by national health system reforms, essentially in Europe. Within this context, only a few players – including MEDICREA – are recording positive growth.

“Our first-half sales were up by more than +20% on the US market, which has exceptional potential for the Group. Our innovation and sales development strategy remains focused on the complex spinal surgery segment. This specialization aims to make MEDICREA a major player in this segment in which we are managing to take market share from our US competitors, accentuate our research and maintain a high margin”, says Denys SOURNAC, Chairman and CEO of MEDICREA.

The Group has successively reported monthly, quarterly and half-yearly sales records thanks to the development of its US, British and French subsidiaries and its deployment in new markets, especially in Asia with distribution operations launched in four more countries since the start of the year. *“This strategy is enabling us to gradually concentrate the bulk of our sales in geographical regions where margins are higher and to reduce our exposure to the European market, which is less profitable and where prices will continue to fall”,* continues Denys SOURNAC.

With a monthly operational break-even point of 1.7 million euros and an average gross margin that is continuing to improve and is approaching 80%, the Group will record a significant operating profit and a positive net profit for the first half-year of 2013.

“Delivering profits for the first time since the creation of MEDICREA represents a major milestone in our Company’s history and validates a long-term investment strategy initiated and deployed thanks to the support from 2002 onwards of private and institutional visionary investors willing to make forward-looking brave choices and sound decisions. I would like to take this opportunity, on behalf of the Company, to thank them all for their unwavering trust that has led to the creation of an innovative, profitable and ambitious French Small and Medium-size Enterprise” concludes Denys SOURNAC.

OUTLOOK

The business outlook is good, notably in the United States where the Group's sales growth should remain strong over the second half of the year.

It is anticipated that 2013 annual net income and profits will be substantially up compared to the previous year, during which the Group almost broke even in operational terms.

A progress meeting will be held at the end of July with the FDA regarding the K-JAWS® cervical compressive staple's product approval file.

Next publication: Results for the 1st half of 2013: October 15th 2013, after market.

ABOUT MEDICREA (www.medicrea.com)

MEDICREA specializes in the design, development, manufacture and distribution of orthopedic implants dedicated to spinal surgery. In a \$10 billion market, MEDICREA is a very dynamic small to medium-sized business of 105 employees with unique innovation capabilities. The Company enjoys an excellent and ever-improving reputation and develops unique relationships with the most visionary and creative spine surgeons in France, the UK, and the USA. Products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specialized in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques. The Group's headquarters are based near Lyon, France, and it also has a manufacturing facility located in La Rochelle as well as three distribution subsidiaries in the USA, the UK and France.

Contacts:

MEDICREA

Denys Sournac, Chairman and Chief Executive Officer

Tel: +33 (0)4 72 01 87 87 - dsournac@medicrea.com

Fabrice Kilfiger, Chief Financial Officer

Tel: +33 (0)4 72 01 87 87 - fkilfiger@medicrea.com

NewCap.

Financial Communication / Press and Investor Relations

Sophie Boulila / Pierre Laurent

Tel: +33 (0)1 44 71 94 91

medicrea@newcap.fr



**MEDICREA is listed on ALTERNEXT by NYSE - Euronext Paris
ISIN: FR 0004178572 – Ticker: ALMED**